Histone Deacetylase (HDAC) Inhibition as a Novel Treatment for Diabetes Mellitus
2011; BioMed Central; Volume: 17; Issue: 5-6 Linguagem: Inglês
10.2119/molmed.2011.00021
ISSN1528-3658
AutoresDan Ploug Christensen, Mattias Salling Dahllöf, Morten Lundh, Daniel N Rasmussen, Mette Damgaard Nielsen, Nils Billestrup, Lars Groth Grunnet, Thomas Mandrup‐Poulsen,
Tópico(s)Genetics and Neurodevelopmental Disorders
ResumoBoth common forms of diabetes have an inflammatory pathogenesis in which immune and metabolic factors converge on interleukin-1β as a key mediator of insulin resistance and β-cell failure. In addition to improving insulin resistance and preventing β-cell inflammatory damage, there is evidence of genetic association between diabetes and histone deacetylases (HDACs); and HDAC inhibitors (HDACi) promote β-cell development, proliferation, differentiation and function and positively affect late diabetic microvascular complications. Here we review this evidence and propose that there is a strong rationale for preclinical studies and clinical trials with the aim of testing the utility of HDACi as a novel therapy for diabetes.
Referência(s)